A computational immunoengineering biotechnology company that developed antibody discovery, optimization, and analysis platforms
A computational immunoengineering biotechnology company that developed antibody discovery, optimization, and analysis platforms. It combined computational immunology, bioengineering, machine learning, and automated methods to create high-affinity human antibody libraries and support monoclonal antibody therapeutics, antibody and cell and gene therapy candidates, and vaccine research. Acquired by Charles River Laboratories in December 2020.